FR05C0022I1 - - Google Patents

Info

Publication number
FR05C0022I1
FR05C0022I1 FR05C0022C FR05C0022I1 FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed filed Critical
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 true FR05C0022I1 (et) 2005-06-10
FR05C0022I2 FR05C0022I2 (et) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (et) 1995-03-30 2005-05-09

Country Status (36)

Country Link
US (1) US6417191B1 (et)
EP (1) EP0817637B1 (et)
JP (1) JP2954357B2 (et)
KR (1) KR100542536B1 (et)
CN (1) CN1103593C (et)
AP (1) AP652A (et)
AT (1) ATE220551T1 (et)
AU (1) AU715213B2 (et)
BR (3) BRPI9612992B1 (et)
CA (1) CA2216634C (et)
CZ (1) CZ295940B6 (et)
DE (3) DE69622386T2 (et)
DK (1) DK0817637T3 (et)
EA (1) EA000626B3 (et)
EE (1) EE04047B1 (et)
ES (1) ES2179193T3 (et)
FR (1) FR05C0022I2 (et)
GE (1) GEP20022647B (et)
HK (1) HK1009401A1 (et)
HU (1) HU224010B1 (et)
IL (1) IL117727A (et)
LU (1) LU91171I2 (et)
MX (1) MX9707316A (et)
MY (1) MY115461A (et)
NL (1) NL300195I2 (et)
NO (2) NO313787B1 (et)
NZ (1) NZ306419A (et)
OA (1) OA10616A (et)
PL (1) PL187085B1 (et)
PT (1) PT817637E (et)
RO (1) RO117995B1 (et)
SI (1) SI0817637T1 (et)
SK (1) SK283825B6 (et)
TR (1) TR199701074T1 (et)
UA (1) UA60293C2 (et)
WO (1) WO1996030025A1 (et)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213217T3 (es) * 1996-06-25 2004-08-16 Glaxo Group Limited Combinaciones que comprenden vx478, zidovudina, y 3tc para uso en el tratamiento de infecciones por vih.
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP0979082A1 (en) * 1997-05-17 2000-02-16 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
JP4485520B2 (ja) 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
BRPI0415533A (pt) 2003-10-24 2006-12-26 Immunaid Pty Ltd método de terapia
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
AU2008213744B2 (en) * 2007-02-09 2013-12-05 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
PE20160180A1 (es) 2010-01-27 2016-05-04 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos.
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106715456B (zh) 2014-08-12 2023-08-29 莫纳什大学 定向淋巴的前药
CN114031658A (zh) 2015-09-08 2022-02-11 莫纳什大学 定向淋巴的前药
EP3675838A4 (en) * 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODUCTS DIRECTED TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CN115348864A (zh) 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
EP0513917B2 (en) 1991-05-16 2001-03-07 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
CZ429398A3 (cs) 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
ES2213217T3 (es) 1996-06-25 2004-08-16 Glaxo Group Limited Combinaciones que comprenden vx478, zidovudina, y 3tc para uso en el tratamiento de infecciones por vih.
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
AP9701089A0 (en) 1997-10-31
LU91171I9 (et) 2018-12-28
IL117727A (en) 1999-11-30
DE122005000029I2 (de) 2006-04-27
US6417191B1 (en) 2002-07-09
NO2005014I2 (no) 2008-02-11
BR9607851B1 (pt) 2009-01-13
NO974510L (no) 1997-09-29
NO2005014I1 (no) 2005-06-06
CZ295940B6 (cs) 2005-12-14
AU715213B2 (en) 2000-01-20
PL187085B1 (pl) 2004-05-31
MY115461A (en) 2003-06-30
DE122005000029I1 (de) 2005-10-06
UA60293C2 (uk) 2003-10-15
HUP9801571A3 (en) 2001-04-28
ATE220551T1 (de) 2002-08-15
SK129597A3 (en) 1998-07-08
EA199700203A1 (ru) 1998-02-26
CN1103593C (zh) 2003-03-26
EP0817637B1 (en) 2002-07-17
CA2216634A1 (en) 1996-10-03
RO117995B1 (ro) 2002-12-30
MX9707316A (es) 1997-11-29
KR19980703420A (ko) 1998-11-05
EA000626B3 (ru) 2016-04-29
AP652A (en) 1998-06-19
EP0817637A1 (en) 1998-01-14
DK0817637T3 (da) 2002-11-11
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
JPH10511682A (ja) 1998-11-10
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
CZ309097A3 (cs) 1998-05-13
KR100542536B1 (ko) 2006-03-23
NO974510D0 (no) 1997-09-29
SI0817637T1 (en) 2002-10-31
ES2179193T3 (es) 2003-01-16
BRPI9612992B1 (pt) 2020-08-04
IL117727A0 (en) 1996-07-23
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
BRPI9607851B8 (pt) 2019-11-05
BR9607851A (pt) 1998-07-21
AU5497296A (en) 1996-10-16
CN1185110A (zh) 1998-06-17
NO313787B1 (no) 2002-12-02
GEP20022647B (en) 2002-03-25
OA10616A (en) 2001-03-15
CA2216634C (en) 2004-07-20
JP2954357B2 (ja) 1999-09-27
NL300195I2 (nl) 2005-11-01
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
FR05C0022I2 (et) 2005-10-21
DE69622386T2 (de) 2003-02-13
HU224010B1 (hu) 2005-04-28
HK1009401A1 (en) 1999-09-10
LU91171I2 (fr) 2005-07-04
PL322532A1 (en) 1998-02-02
EA000626B1 (ru) 1999-12-29
EE04047B1 (et) 2003-06-16
EE9700240A (et) 1998-04-15

Similar Documents

Publication Publication Date Title
DE69638352D1 (et)
DE69637714D1 (et)
FR05C0022I2 (et)
BR122012014331A2 (et)
BRPI9612258B1 (et)
BRPI9612138B1 (et)
DK143195A (et)
IN186887B (et)
IN186501B (et)
IN182969B (et)
DK0727898T3 (et)
FR2729785B1 (et)
DK126096A (et)
IN182291B (et)
IN182456B (et)
IN185244B (et)
BR7502120U (et)
IN186166B (et)
BR7501503U (et)
AU1627395A (et)
CN3031350S (et)
CN3034524S (et)
CN3034591S (et)
CN3035871S (et)
CN3035870S (et)